Abstract
Introduction
Intanza®/IDflu® (Sanofi Pasteur SA, Lyon, France), a split-virion, trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available in adults 18–59 years of age (9 μg) and ≥60 years of age (15 μg) as of the 2010/2011 northern hemisphere influenza season.
Methods
This study assessed the acceptability of intradermal vaccination with Intanza/IDflu in routine clinical practice in adult vaccinees and their vaccine prescribers. Vaccine prescribers and adults who had elected to be vaccinated with Intanza/IDflu during the 2010/2011 northern hemisphere influenza season were recruited to complete surveys about their opinions of influenza vaccination and their acceptance of the intradermal vaccination. Czech subjects 18–59 years of age were vaccinated with the 9 μg formulation and those ≥60 years of age with the 15 μg formulation of Intanza/IDflu. All Turkish subjects were vaccinated with the 9 μg formulation, as Intanza/IDflu 15 μg was not available in Turkey at the time the survey was conducted.
Results
One thousand and twelve vaccinees and 28 vaccine prescribers in the Czech Republic, and 249 vaccinees and 15 vaccine prescribers in Turkey completed questionnaires. Overall, 96.1% of vaccinees were satisfied or very satisfied with Intanza/IDflu. The main reason for satisfaction was that the injection was considered minimally painful. Most (93.9%) vaccinees reported that they would prefer to receive the same vaccination next year. Furthermore, 95.3% of vaccine prescribers were satisfied or very satisfied with the intradermal vaccine, and 82.6% preferred intradermal over intramuscular vaccination.
Conclusions
Intradermal vaccination for seasonal influenza using Intanza/IDflu is well accepted by adult vaccinees and vaccine prescribers. By providing an additional, well-accepted method, Intanza/IDflu might help increase seasonal influenza vaccination rates in adults.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Monto AS. Seasonal influenza and vaccination coverage. Vaccine. 2010;28(suppl. 4):D33–D44.
World Health Organization. Influenza (seasonal). Available at: http://www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed October 6, 2011.
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186.
Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499–505.
Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health. 1986;76:761–765.
Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798–811.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–5096.
Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health. 2010;10:724.
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333:889–893.
Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655–1663.
World Health Organization. Resolution of the World Health Assembly WHA 56.19. Prevention and control of influenza pandemics and annual epidemics. 56th World Health Assembly, Geneva 2003.
The Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union. 2009;L348:71–72.
Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62.
Centers for Disease Control. Healthy People 2020 Summary of Objectives. Available at: http://healthypeople.gov/2020/topicsobjectives2020/pdfs/Immunization.pdf. Accessed March 7, 2011.
Centers for Disease Control and Prevention. Interim results: state-specific seasonal influenza vaccination coverage — United States, August 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:477–484.
Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369–393.
Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25:8833–8842.
European Medicines Agency. Assessment report for Intanza® Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000957/human_med_000842.jsp&curl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true. Accessed December 2, 2011.
Arnou R, Eavis P, Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, phase III trial. Hum Vaccin. 2010;6:346–354.
Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.
Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 2009;7:13.
Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198:650–658.
Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine. 2008;26:6614–6619.
Güvenlik Kurumu Saslık Uygulama Talimatı. Directive for Practice of Health. Available at: http://www.sgk.gov.tr/wps/portal/ESGK/GSS. Accessed December 2, 2011.
Blank PR, Szucs TD. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Rev Vaccines. 2009;8:425–433.
Eizenberg P, Booy R, Naser N, et al. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther. 2011;28:640–649.
Reygrobellet C, Viala-Danten M, Meunier J, et al. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6:336–345.
Arnou R, Frank M, Hagel T, et al. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Ther. 2011;28:555–565.
Author information
Authors and Affiliations
Corresponding author
Additional information
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Prymula, R., Usluer, G., Altinel, S. et al. Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey. Adv Therapy 29, 41–52 (2012). https://doi.org/10.1007/s12325-011-0090-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0090-5